Dea No. 9170

Dea No. 9170 Brand names, Dea No. 9170 Analogs

Dea No. 9170 Brand Names Mixture

Lomotil (Atropine Sulfate + Diphenoxylate Hcl)

Dea No. 9170 Chemical_Formula

C₃₀H₃₂N₂O₂

Dea No. 9170 RX_link

http://www.rxlist.com/cgi/generic3/diphenoxylate.htm

Dea No. 9170 fda sheet

Dea No. 9170 msds (material safety sheet)

Dea_No._9170 MSDS

Dea No. 9170 Synthesis Reference

Janssen, U.S. pat. 2,898,340 (1959)

Dea No. 9170 Molecular Weight

452.587 g/mol

Dea No. 9170 Melting Point

221 ^oC

Dea No. 9170 H₂O Solubility

0.8 mg/ml

Dea No. 9170 State

Solid

Dea No. 9170 LogP

7.385

Dea No. 9170 Dosage Forms

Oral solution; Tablet

Dea No. 9170 Indication

For as adjunctive therapy in the management of diarrhea

Dea No. 9170 Pharmacology

Diphenoxylate, an antidiarrheal, is effective as adjunctive therapy in the management of diarrhea. Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood.

Dea No. 9170 Absorption

90%

Dea No. 9170 side effects and Toxicity

Coma, dry skin and mucous membranes, enlarged pupils of the eyes, extremely high body temperature, flushing, involuntary eyeball movement, lower than normal muscle tone, pinpoint pupils, rapid heartbeat, restlessness, sluggishness, suppressed breathing

Dea No. 9170 Patient Information

INFORM THE PATIENT (PARENT OR GUARDIAN) NOT TO EXCEED THE RECOMMENDED DOSAGE AND TO KEEP DIPHEN-OXYLATE HCL AND ATROPINE SULFATE OUT OF THE REACH OF CHILDREN AND IN A CHILD-RESISTANT CONTAINER, INFORM THE PATIENT OF THE CONSEQUENCES OF OVERDOSAGE, INCLUDING SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH.

Diphenoxylate HCl and atropine sulfate may produce drowsiness or dizziness. The patient should be cautioned regarding activities requiring mental alertness, such as driving or operati ng dangerous machinery. Potentiation of the action of alcohol, barbiturates and tranquilizers with concomitant use of diphenoxylate HCl and atropine sulfate should be explained to the patient. The physician should also provide the patient with other information in this labeling, as appropriate.

Dea No. 9170 Organisms Affected

Humans and other mammals